Food and Drug Administration

The Food and Drug Administration (FDA) is presented as the United States regulator that protects the public by ensuring the safety of food, drugs, medical devices, and cosmetics. Under POSIWID, its repeated output since 1992 is the issuance of legitimacy stamps to products whose review it is paid by the manufacturer to conduct, under a food-additive regime in which the manufacturer decides its own product is safe and need not notify the regulator.

Stated Purpose

The agency's mission statement: "protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation."

Origin

The 1906 Pure Food and Drug Act followed public reaction to Upton Sinclair's The Jungle. Sinclair's own assessment: "I aimed at the public's heart, and by accident I hit it in the stomach." The inspection regime that resulted imposed costs that small meatpackers could not bear and gave the large packers a government stamp for export. Gabriel Kolko's The Triumph of Conservatism (1963) argues that most Progressive-era regulation was sought by the dominant firms for this reason. The historiography is contested; the pattern it describes — regulation as a moat around incumbents — recurs throughout the record.

Two later acts were genuine responses to body counts:

1938 Food, Drug, and Cosmetic Act — after Elixir Sulfanilamide (diethylene glycol solvent; around a hundred deaths). Required proof of safety before marketing.
1962 Kefauver–Harris Amendment — after thalidomide. Required proof of efficacy. The FDA's Frances Kelsey had blocked thalidomide in the United States on the existing rules; the agency functioned as described.

The agency has therefore protected consumers in specific episodes. The structural question is what its funding and procedures have rewarded since.

The Funding Structure

The Prescription Drug User Fee Act (PDUFA, 1992) permits the FDA to collect fees from pharmaceutical companies for reviewing their applications. By the 2020s, user fees fund roughly half of the agency's total budget and around two-thirds or more of its drug-review centre — approximate figures, but the order of magnitude is not disputed.

PDUFA is reauthorised every five years. The reauthorisation includes performance goals — review timelines the FDA commits to meet — negotiated directly between the agency and the industry that pays the fees.

The structure: the regulated party pays the regulator per application, and sets the speed targets. Revenue scales with throughput. Published research (Carpenter et al.) found that drugs approved just before PDUFA deadlines had higher rates of later safety problems than drugs approved at other times.

Decision Power Map

Role	Formal power	Effective power	Accountability
HHS Secretary	Declares public health emergencies; issues PREP Act liability immunity	Sets the conditions under which the FDA's normal standards are suspended	Political appointee
FDA leadership	Approves, authorises, withdraws	Constrained by PDUFA targets; subject to post-tenure employment by the regulated industry	See revolving door below
Industry	Submits applications; self-affirms food additives as safe	Funds the review; negotiates review targets; selects its own safety experts	Product liability — suspended under PREP declarations
Advisory committees	Recommend approval or rejection	Recommendations are non-binding; members frequently carry disclosed industry ties	—
Consumer	None	None	Bears the error

The Revolving Door

Official	FDA role	Subsequent or prior position
Curtis Wright	Medical review officer who approved OxyContin (1995), including a label stating that delayed absorption "is believed to reduce the abuse liability"	Joined Purdue Pharma within two years
Mark McClellan	Commissioner 2002–04	Johnson & Johnson board
Scott Gottlieb	Commissioner 2017–19	Pfizer board (2019)
Stephen Hahn	Commissioner 2019–21	Flagship Pioneering, the venture firm that founded Moderna
Robert Califf	Commissioner 2016–17 and 2022–25	Extensive pharmaceutical consulting prior to both terms

Vioxx (Merck; approved 1999, withdrawn 2004) is the reference case for what the structure produces. In Senate testimony in 2004, the FDA's own drug-safety officer David Graham described the agency as "incapable of protecting America" from a repeat.

Food Additives and GRAS

The 1958 Food Additives Amendment created an exemption for substances Generally Recognised As Safe (GRAS). The FDA subsequently formalised GRAS as a voluntary notification system: a manufacturer may determine for itself that an additive is safe, using experts it selects, and is not required to inform the FDA. The agency has estimated that around a thousand substances are in the food supply under self-affirmed GRAS with no notification.

A 2013 study in JAMA Internal Medicine (Neltner et al.) examined 451 GRAS determinations:

22% were made by an employee of the manufacturer
13% by a consultancy the manufacturer hired
64% by a panel selected by the manufacturer or its consultant
0% by anyone independent of the manufacturer

This is not regulatory capture. It is abdication as the written procedure.

The Default

The European Union applies the precautionary principle: the manufacturer demonstrates safety before entry. The United States applies GRAS: the regulator must demonstrate harm after entry. Under front-door ethics, the US system makes entry easy and removal difficult. Under the question of who bears error: the consumer, until harm is proven.

Substance	Status elsewhere	Status in the United States
Potassium bromate (flour treatment)	Banned in the EU, UK, Canada, Brazil	Permitted; California ban effective 2027
Titanium dioxide (whitener)	EU ban 2022	Permitted
Azodicarbonamide (dough conditioner)	Banned in the EU and Australia	Permitted
Brominated vegetable oil	Banned in the EU and Japan	Permitted until 2024
Ractopamine (livestock feed)	Banned in around 160 countries, including the EU, China, and Russia	Permitted
rBGH / rBST (dairy hormone)	Banned in the EU and Canada	Permitted
Red Dye No. 3	—	Banned in cosmetics in 1990 as a carcinogen in rats; permitted in food until January 2025

Red Dye No. 3 is the cleanest single case: the same agency, on the same evidence, prohibited the substance on skin and permitted it for ingestion for thirty-five years.

Nutrition Education as Industry Product

Public ignorance of what constitutes a meal — of how nutrition and toxicity work — is frequently attributed to poor consumer education. The attribution is correct, but the failure is in the input, not the person. The educational content itself was supplied by the parties the regulation was meant to constrain:

In 1967 the Sugar Research Foundation paid Harvard researchers for a New England Journal of Medicine review that shifted the dietary blame for heart disease from sugar to fat. The payment was documented from the Foundation's own internal records (Kearns et al., JAMA Internal Medicine, 2016).
The 1992 USDA food pyramid's grain-heavy base has been attributed by the nutritionist who led its original design to revisions made under agricultural lobbying.
Nutrition labelling was designed with industry input and teaches label-reading — a skill for navigating processed products — rather than cooking.

The result is a population that treats processed supermarket food as equivalent to a prepared meal, having been taught a curriculum written by the processors. This is the Input Constraint operating one level below the journal — at the school.

Emergency Powers

The FDA formally retains authority during a declared emergency: it issues the Emergency Use Authorisation (EUA; Section 564 of the FD&C Act, added 2004). Under an EUA, the standard drops from "safe and effective" to "may be effective," with known and potential benefits judged to outweigh known and potential risks.

Effectively, the emergency framework routes around the agency's protective functions while retaining its legitimacy function:

The trigger is above the agency. The HHS Secretary declares the emergency; the FDA's EUA authority activates on that declaration.
Liability is removed above the agency. The PREP Act (2005) grants manufacturers, distributors, and administrators of covered countermeasures immunity from suit, except for wilful misconduct — a standard requiring proof of intent that has not succeeded in practice. The immunity is issued by HHS. It removes the tort feedback loop by which harm becomes cost to the manufacturer. The replacement, the Countermeasures Injury Compensation Programme, has a one-year filing window, no appeal to the courts, and has compensated a small fraction of claims filed.
The agency's own staff were overridden. In 2021 the FDA's two most senior vaccine officials, Marion Gruber and Philip Krause, resigned — reportedly over White House pressure to authorise boosters before the agency had reviewed the data — and subsequently co-authored a Lancet article arguing against boosters for the general population.
The agency's data behaviour served the manufacturer. In PHMPT v. FDA (2021), the FDA proposed releasing the Pfizer licensing documents at 500 pages per month — a schedule of roughly 75 years. Pfizer intervened in support. The court ordered release at 55,000 pages per month. The regulator sought to withhold the data on which it had licensed the product for longer than any living person would live.

During an emergency, the FDA becomes a stamp: "FDA-authorised" remains on the product while the full-trial standard, manufacturer liability, and data transparency are suspended by other actors.

The Loop

This section is inferred, not observed.

One division of the agency permits additives to enter the food supply under GRAS self-affirmation with no notification. The resulting metabolic disease — obesity, diabetes, cardiovascular conditions — is managed by drugs that another division of the same agency approves. The agency's fee revenue comes from the drug side.

Nothing in this structure rewards prevention. The additive enters through a door no one watches; the treatment is paid per application. Intent cannot be observed from the structure. The incentive can.

What Would Weaken This Interpretation

Evidence that GRAS self-affirmed additives, when independently audited, have a safety record comparable to FDA-reviewed additives.
Evidence that decisions by officials who later joined industry do not differ from those of officials who did not.
Evidence that the Countermeasures Injury Compensation Programme compensates at rates comparable to the tort system it replaced.
Evidence that drugs approved near PDUFA deadlines do not have elevated later-withdrawal rates. The published research runs the other way.
Evidence that nutrition curricula were developed independently of producer funding.

Stance

Contest "FDA-approved" as a terminal credential. It means "met a fee-funded review's threshold at the time of approval," not "safe."
Reform: funding from general revenue rather than user fees; mandatory GRAS notification; precautionary burden on the manufacturer; cooling-off periods between agency office and industry employment.
Exit: cooking from whole ingredients removes most GRAS exposure. This exit is not equally available — it requires time, money, and access that food deserts and low wages remove — and individual exit does not substitute for structural accountability.

Epistemic Status

The funding structure, the revolving-door cases, the GRAS procedure, the Neltner findings, the additive comparisons, the Kearns documentation, the EUA and PREP provisions, the Gruber–Krause resignations, and the PHMPT filing are observed — matters of public record. The Kolko reading of the 1906 origin is reported and contested. The loop between the food and drug divisions is inferred from structure. The claim that the education pipeline causes the observed dietary outcomes is provisional — the funding and lobbying are documented; the causal weight relative to other factors is not resolved here.